European Multi-Centre Post-Market Registry on Thoracic Endovascular Arch Repair Using Castor™ and Cratos™ (CEDAR)
European Multi-Centre Castor™ and Cratos™ Branched Endovascular Arch Repair Registry
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Maggie Shen, MD MSc
- Phone Number: 00441235750800
- Email: maggie.shen@endovastec-lm.com
Study Contact Backup
- Name: Anne Woodman
- Phone Number: 00441235750800
- Email: anne.woodman@endovastec-lm.com
Study Locations
-
-
-
Hamburg, Germany, 20099
- Recruiting
- ASKLEPIOS Kliniken St. Georg
-
Contact:
- Prof. Dr. med.
- Phone Number: 2492 004940181885
- Email: t.koeppel@asklepios.com
-
Principal Investigator:
- Thomas A Koeppel, Prof. Dr. med.
-
Sub-Investigator:
- Hans Christian Voigt, Dr. med. univ.
-
Münster, Germany, 48149
- Recruiting
- Universitätsklinikum Münster (UKM)
-
Contact:
- Jana Ebing
- Phone Number: 00492518351717
- Email: vital@ukmuenster.de
-
Principal Investigator:
- Alexander Oberhuber, Dr. med. univ.
-
-
-
-
-
Sion, Switzerland, 1951
- Recruiting
- Hopital de Sion
-
Contact:
- Daniel Danzer
- Phone Number: 0041276034124
- Email: daniel.danzer@hopitalvs.ch
-
Principal Investigator:
- Daniel Danzer
-
Zurich, Switzerland, CH-8091
- Recruiting
- Universitätsspital Zürich (USZ)
-
Contact:
- Susanne Menz
- Phone Number: 0041432530243
- Email: Susanne.Menz@usz.ch
-
Principal Investigator:
- Alexander Zimmermann, Prof. Dr. med.
-
Sub-Investigator:
- Benedikt Reutersberg,, PD Dr. med.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Implantation of a Castor™ or Cratos™ single branch endoprothesis with incorporation of the left subclavian artery
- Age >18 years
Exclusion Criteria:
- Patients allergic to the materials of the device;
- Patients with severe or potentially systemic infections that increase the chance of graft infection;
- Minors and pregnant women;
- Branch for other supra-aortic vessels than the LSA
- Rejection of participation.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Cohort 1: patients treated with Castor™
Arch involving aortic pathologies treated with the Castor™ stent graft system.
|
Treatment of subjects diagnosed with thoracic aortic pathologies using the Castor™ Branched Aortic Stent-Graft and Delivery System.
Follow up as per institutional standard of care.
|
|
Cohort 2: patients treated with Cratos™
Arch involving aortic pathologies treated with the Cratos™ stent graft system.
|
Treatment of subjects diagnosed with thoracic aortic pathologies using the Cratos™ Branched Aortic Stent-Graft and Delivery System.
Follow up as per institutional standard of care.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
30-day all-cause mortality
Time Frame: 30 days
|
A measure of the total number of patients participating in the CEDAR study who die from any cause within 30 days of the implantation of the branched aortic stent graft - Castor™ or Cratos™.
|
30 days
|
|
Technical success rate
Time Frame: 24 hours
|
Technical Success is defined as successful access and deployment of the endograft, including implantation of the branch into the target vessel, with patency of the branch and no evidence of type I or type III endoleak on completion angiography or cone-beam computed tomography.
Additional intra-operative measures to achieve this, such as ballooning or branch extension with additional stent grafts, are also considered as primary technical success.
|
24 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical success rate at 30 days, 6 months and at 1 - 5 years
Time Frame: at 30 days, 6 months and at 1 - 5 years
|
This is defined as Technical Success plus the absence of aortic related death, aortic rupture, graft infection, sac expansion > 5mm, graft migration >10mm, persistent endoleaks type I and III requiring re-intervention, conversion to open surgery, permanent paraplegia, disabling stroke or permanent dialysis.
|
at 30 days, 6 months and at 1 - 5 years
|
|
Rate of Endoleak
Time Frame: at 30 days, 6 months, and at 1 - 5 years
|
at 30 days, 6 months, and at 1 - 5 years
|
|
|
Branch occlusion rate
Time Frame: at 30 days, 6 months, and 1-5 year
|
at 30 days, 6 months, and 1-5 year
|
|
|
Rate of perioperative retrograde type A aortic dissections
Time Frame: 30 days, 6 months, and at 1 - 5 years
|
30 days, 6 months, and at 1 - 5 years
|
|
|
Rate of reintervention
Time Frame: at 30 days, 6 months, and at 1-5 years
|
at 30 days, 6 months, and at 1-5 years
|
|
|
Combined endpoint major adverse events
Time Frame: at 30-days, 6 months and 1 year
|
all-cause mortality, myocardial infarction, respiratory failure with postoperative prolonged mechanical ventilation > 24h, renal function declining in a GFR > 50% reduction to perioperative, bowel ischemia requiring surgical resection, major stroke and permanent paraplegia.
|
at 30-days, 6 months and 1 year
|
|
Incidence rate of spinal cord ischemia for the duration of the study
Time Frame: at 30 days, 6 months, and at 1 - 5 years
|
at 30 days, 6 months, and at 1 - 5 years
|
|
|
Stroke rate
Time Frame: at 30 days, 6 months, and at 1 - 5 years
|
at 30 days, 6 months, and at 1 - 5 years
|
|
|
All-cause mortality
Time Frame: at 30 days, 6 months, and at 1 - 5 years
|
at 30 days, 6 months, and at 1 - 5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Jing Wang, Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Dissection, Blood Vessel
- Acute Aortic Syndrome
- Vascular Diseases
- Cardiovascular Diseases
- Pathologic Processes
- Hemorrhage
- Arteriosclerosis
- Arterial Occlusive Diseases
- Aortic Diseases
- Aneurysm
- Aortic Dissection
- Pathological Conditions, Signs and Symptoms
- Hematoma
- Penetrating Atherosclerotic Ulcer
- Dissection, Thoracic Aorta
- Aortic Intramural Hematoma
- Aortic Aneurysm
- Aortic Aneurysm, Thoracic
Other Study ID Numbers
Other Study ID Numbers
- PMCF-2025-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.